Jiangsu introduced 30 measures to promote the high-quality development of the biomedical industry

On September 24, the Jiangsu Provincial Government held a press conference to release "Several Policies and Measures on Promoting the High-Quality Development of the Province's Biomedicine Industry" (hereinafter referred to as "Several Policy Measures") to promote the open innovation of the entire Jiangsu biomedical industry chain.
Build a nationally leading and globally influential biomedical industry cluster
.
In recent years, Jiangsu Province has listed the biopharmaceutical industry as one of the ten strategic emerging industries and 13 advanced manufacturing clusters to focus on cultivation, promoting the rapid and healthy development of the biopharmaceutical industry
.
At present, the development of the biomedical industry in Jiangsu Province has achieved remarkable results, and the scale of the industry is leading the country
.
In 2020, the output value of the biomedical industry in Jiangsu Province will account for about 1/6 of the country, ranking first in the country
.
In the first half of this year, the output value of Jiangsu's biomedical industry increased by 16.
4% year-on-year
.
Jiangsu's biomedical industry has obvious advantages in innovation capabilities.
During the "13th Five-Year Plan" period, a total of 15 innovative drugs were approved, accounting for nearly 40% of the country, and the number of drug registration applications and approvals ranked first in the country
.
In 2020, the number of patent applications in the field of biomedicine in Jiangsu Province exceeded 10,000, and the number of authorized patents exceeded 5,000, ranking first in the country.
It was approved as the country's first national biopharmaceutical technology innovation center
.
Since last year, in the coordinated promotion of epidemic prevention and control and economic and social development, the biomedical industry in Jiangsu Province has achieved an upswing against the trend.
Key products such as vaccines, nucleic acid detection reagents, and ventilators have played an important role in winning the battle against epidemic prevention and control.

.
The main purpose of Jiangsu's "Several Policy Measures" is to optimize and strengthen the province's biomedical industry supply chain, and promote the high-quality development of Jiangsu's biomedical industry to a new level
.
The "Several Policy Measures" proposes 30 policy measures from 7 aspects: industrial development goals, product development, review and approval, manufacturing, application and promotion, talent recruitment, and industrial ecology, forming a "policy package" covering the entire industry chain.
Embodies 4 characteristics
.
Highlight the creation of a highland for industrial development
.
With the goal of improving the status of Jiangsu's biomedical industry in the global industrial chain, innovation chain, supply chain, and value chain, we will continue to forge the long board and make up for the short board, and strengthen the systemic policy supply.
Through three years of hard work, the province's biomedical industry The basic capabilities of the pharmaceutical industry and the modernization level of the industrial chain have been further improved, and the proportion of innovative drugs and high-end medical devices with independent intellectual property rights has increased significantly
.
Highlight the cultivation of innovative enterprise clusters
.
Adhere to the dominant position of enterprises, provide personalized services and precise support around the development needs of biomedical enterprises, promote the gathering of innovative elements such as talents, technology, capital, and data to enterprises, and strive to cultivate innovative enterprise clusters with global competitiveness
.
Focusing on cultivating and growing innovative leading enterprises, it is proposed to support leading enterprises to strengthen capital operation and become bigger and stronger; to support leading enterprises to take the lead in forming innovative consortia to promote the integration and innovation of upstream and downstream of the industrial chain, large and small enterprises; support and encourage global benchmark biomedical companies in Jiangsu set up regional headquarters, research and development centers, production bases and so on
.
Give prominence to the role of the market and the government
.
Promote the better integration of effective markets and effective governments, continue to deepen the reform of "delegation, regulation, and service", focus on optimizing review and approval procedures and services, and stimulate the vitality of market entities and social creativity
.
In terms of deepening the reform of the drug review system, it is proposed to establish and improve a mechanism for branch classification, segmented and graded review, and to further reduce the time limit for review and approval; in terms of innovative biomedical financial services, it is proposed to explore new financing models such as intellectual property securitization to give full play to the government The role of investment funds and venture capital funds to support pharmaceutical research and development and the industrialization of results
.
Prominent problem-oriented and precise force
.
Identify the key links and weak bottlenecks that restrict the development of the biomedical industry, formulate targeted policies and measures, and focus on solving key and difficult problems
.
In view of the key nodes of the new drug research and development pipeline, according to the phase I, II, III clinical trials and the production stage of the market, different levels of support will be given to innovative drugs and improved new drugs; in response to market demand for key raw materials, high-end excipients, and important consumables, Choose a region where conditions permit to build a green and efficient production base to provide biomedical companies with small batch, low-cost, customized key material supply
.